学士论文--中国医药产业的国际竞争力研究

毕业论文论文题目：中国医药产业的国际竞争力研究姓名张锦明学号070401130专业国际经济与贸易班级07国贸1班摘要本文站在客观事实的层面，以真实数据为依据，从经济学、社会学的角度，系统地分析了当前中国医药产业的发展状况，并提出恳诚的建议。在文中的第一、二章节中，主要运用了归纳演绎法与统计分析法，介绍了世界医药市场的概况，对中国现有医药行业体系及运营情况作出分析。第三章运用比较分析法，分别对中国化学制药、生物制药、中医药板块作出评述，并指出医药行业整体的产业链结构与研发生产力的存在问题。第四章主要运用了趋势分析法，针对中国医药产业的现状与前景，提出可行、有效的战略性发展方案。关键词研发产业链医改创新整合abstractThispaperstandedintheobjectivefactslevels,withrealdataasthebasis,fromtheAngleofeconomicsandsociology,systematicallyanalyzedthecurrentChinesemedicineindustrydevelopment,andSincerelyputforwardtheheartfeltSuggestions.Inthetextofthefirstandsecondchapter,mainlyutilizedinducedeductionandstatisticalanalysis,thispaperintroducedthesituationofinternationalmedicalmarketofChinapharmaceuticalindustrysystemandmakeananalysisofoperationcondition.Usingcomparativeanalysisrespectively,thethirdchaptermadecommentsoftheChinesechemicalpharmacy,biologicpharmacy,TCMplate,andpointedouttheproblemsofpharmaceuticalindustrychainstructureanddevelopmenceofproductivity.Thefourthchapterbasicallyusedatrendanalysisonthesituationandprospectofchinesemedicineindustry,andproposeafeasibleandeffectivestrategicdevelopmentplan.keywordsR&DIndustryChainhealthcarereformInnovationConsolidation目录前言1国际医药贸易概况······················································1.1世界医药行业基本情况··············································1.22010年2季度主要产品进出口情况···································1.2.1医药品························································1.2.2抗菌素（制剂除外）·············································1.2.3抗菌素制剂···················································1.2.4中式成药·····················································2中国医药行业状况······················································2.1行业规模与市场分析················································2.1.1行业规模······················································2.1.2市场分析······················································2.2行业财务分析与运营状况············································2.2.1产销情况······················································2.2.2盈利情况······················································2.2.3行业运营绩效··················································3中国医药产业国际竞争力水平剖析········································3.1三大药种的产业竞争力分析··········································3.1.1生物医药产业分析··············································3.1.2化学药产业分析················································3.1.3中医药产业分析················································3.2中国医药产业链结构分析············································3.2.1产业链总体概况················································3.2.2主要特征······················································3.2.3专注铸就成功··················································3.3中国医药产业的研发生产力分析······································3.3.1医药产业特征··················································3.3.2研发生产力分析················································4如何提升我国医药产业的国际竞争力······································4.1中国医药产业未来预测未来预测······································4.2我国政府对支持医药产业发展的措施··································4.2.1新医改推动中国医药市场向前发展·································4.2.2新GMP认证制度将迎合我国医药产品质量提升的需求················4.3我们的医药企业该怎样把握新一轮的发展机遇··························4.3.1“有准备”的人在做些什么······································4.3.2确定企业自身方向最重要········································4.3.3整合——中国医药企业的必由之路································4.4全行业的发展该怎样进行············································4.4.1积极发展中医药产业············································4.4.2制药工业的发展之路············································前言根据中国国家药品管理中心(SPAC)的统计，中国医药产业产值过去二十年年均增长率达16.72%，然而，中国的医药行业依然存在规模小，布局分散、生产工艺落后的缺点，生产技术和管理结构过时的缺点。同时，中国医药行业市场集中程度较低及国际贸易竞争力薄弱，再者就是专利药品开发缺乏力度。然而，中国的医药行业依然存在规模小，布局分散、生产工艺落后的缺点，生产技术和管理结构过时的缺点。同时，中国医药行业市场集中程度较低及国际贸易竞争力薄弱，再者就是专利药品开发缺乏力度。随着中国加入世界贸易组织(WTO)，中国医药企业需要更完好地融入全球经济。加入了世贸组织，中国就要遵循WTO的基本原则，比如提高透明度和加强商业法律程序。我国加入wto后，必须承兑的承诺涉及知识产权，关税优惠，和针对从事药品分销的国外供应商的市场准入制度。所有这些举措都为国外医药公司在中国提供分外有利的商业机会，反过来，国际竞争将给中国制药工业以强烈的压力。TheChinesepharmaceuticalindustryhasincreasedinvaluewithanannualaveragegrowthrateof16.72%overthelastfewdecades，ccordingtotheStatePharmaceuticalAdministrationofChina(SPAC).However,theindustryisstillsmall-scale,withascatteredgeographicallayout,duplicatedproductionprocesses,andoutdatedmanufacturingtechnologyandmanagementstructure.TheChinesepharmaceuticalindustryalsohasalowermarketconcentrationandweakinternationaltradingcompetitiveness,coupledwithalackofpatentedpharmaceuticalsdevelopedin-house.However,theindustryisstillsmall-scale,withascatteredgeographicallayout,duplicatedproductionprocesses,andoutdatedmanufacturingtechnologyandmanagementstructure.TheChinesepharmaceuticalindustryalsohasalowermarketconcentrationandweakinternationaltradingcompetitiveness,coupledwithalackofpatentedpharmaceuticalsdevelopedin-house.AsChinajoinstheWorldTradeOrganization(WTO),itneedstointegratemorecompletelyintotheglobaleconomy.TheinternationalcompetitionwillplaceanintensepressureontheChinesepharmaceuticalindustryandfurtheropenthedoortoalucrativemarketfornon-Chinesecompanies,especiallyforpharmaceuticalproducersandmanufacturers.AccessiontotheWTObinds